Showing posts with label Testing. Show all posts
Showing posts with label Testing. Show all posts

Wednesday, June 20, 2012

The NNSA Sequoia supercomputer takes worlds fastest title, preventing nuclear testing

Supercomputer for NNSA Sequoia ranked as the fastest in the world
At the Lawrence Livermore National Laboratory supercomputer passes petaflop 16



WASHINGTON, D.C. - the National Nuclear Security Administration (NNSA) today announced that a supercomputer called Sequoia at the Lawrence Livermore National Laboratory (LLNL) has been ranked the most powerful computer in the world.
The synchronization to 16,32 sustained petaflop (quadrillion floating point operations per second), Sequoia received a standard industry ranking number list Top500 fastest supercomputers in the world published on Monday, June 18, at the International Supercomputing Conference (ISC12) in Hamburg, Germany. Sequoia was built for the NNSA by IBM.
IBM Blue Gene/Q 96 system - rack, Sequoia will allow simulations that explore phenomena at a level of detail never possible. Sequoia is dedicated to NNSA Advanced Simulation and computing program (ASC) for the management of the nuclear stockpiles of the nation, a joint effort of LLNL and National Laboratory in Los Alamos, Sandia National Laboratories.
"Calculation of platforms such as Sequoia at the United States help to maintain its nuclear arsenal safe and secure without the need for underground testing," said NNSA administrator Thomas D'Agostino. "Sequoia can be faster, provides underlying computing capabilities give us confidence in nuclear deterrence of the country has increased as weapons accumulate changes under the agreements of the Treaty, an essential part of the nuclear safety of president Obama. program". Sequoia also represents American leader in high performance computer, key technological innovation leading to economic prosperity and quality jobs. »
"Sequoia will allow a more complete understanding of the performance of weapons, including the hydrodynamics and the properties of materials at temperatures and extreme pressure." In particular, the system will enable the result of calculations of quantifying uncertainty highly committed to support efforts to extend the life of aging weapons systems; "what we call a life extension program (LEP)," said Bob Meisner, NNSA Director CSA program.
Quantification of uncertainty, or "UQ," is the quantitative characterization and reduction of uncertainty in the applications of the computer with very large suites of running calculations to characterize the effects of minor differences in systems. Sources of uncertainty are active in natural sciences and engineering. UQ uses statistical methods to determine the probable results.
The machine will be an important tool used to support programs of life, including the B61 and the W78 extension stocks. By reducing the time required for these studies, the total costs are also reduced. In addition, the machine is intended to improve the ability of the NNSA to maintain stock by resolution of the important results in weapons systems, providing greater power for the annual assessment of the reserve and anticipate and prevent future problems resulting from inevitable aging. This helps to ensure that the nation will never return to nuclear explosive tests.
Superordinateurs as Sequoia helped the United States to have confidence in its stockpile of nuclear weapons in the 20 years since the nuclear tests ended in 1992. The idea, which comes from superinformatiques simulations is also essential to address the issues of non-proliferation and the fight against terrorism as well as inform other decisions of national security as nuclear weapon of political and treaty agreements.
"Sequoia is an exciting achievement for the architecture of power, not only for its speed and efficiency, but also for the important and complex work, it can support to protect the nuclear stockpiles of the country," said Colin Parris, Director general IBM Power Systems. "With supercomputers capable of 16 sustained petaflop, our ability to influence strategic areas change as life, public safety and transportation sciences that make our most intelligent world is more than ever." Improvements of affordability, performance, efficiency and size of Sequoia supply will also a broader set of clients to implement the HPC for their competitive advantage. »
The NNSA/LLNL/IBM partnership has produced six systems HPC which were classified among the most powerful computers in the world, including: the accelerated strategic Computing Initiative (ASCI) Blue Pacific. ASCI white; the Advanced Simulation and computing (ASC), purple; Blue Gene/L; Blue Gene/P; and Blue Gene/Q, Sequoia. ASCI White, Blue Gene/L and now reaches Sequoia a number of ranking on the Top500 list.
Sequoia is mainly water cooled and consists of 96 records; 98 304 compute nodes; core 1.60 million. and 1.6 petabytes of memory. Although orders of magnitude more powerful than such predecessor systems as purple bag and Blue Gene/L, Sequoia will be about 90 times more power efficient that violet and approximately eight times more that BG/L relative to the speed of these systems.

View the original article here

Saturday, May 26, 2012

Honda to Start Testing EVs, PHEVs in Japan


Honda Motor Co Ltd announced Dec 20, 2010, that it will start field tests of its electric vehicle (EV) and plug-in hybrid electric vehicle (PHEV) in Japan.


On the same day, the company showed prototypes of an EV based on the Fit minicar and a PHEV based on the Inspire sedan.


Honda announced a prototype of the EV and the platform of the PHEV at the Los Angeles Motor Show, which took place in November 2010. And the vehicles announced this time were their new versions designed for the Japanese market.


“For expanding the use of EVs, the balance between price and performance is important,” Honda President Takanobu Ito said. “It is still difficult to achieve the balance. But there may be markets in specific regions such as rural areas where there is no service station.”


Honda will conduct the field tests in Saitama and Kumamoto prefectures in Japan. For each field test, five EVs and five PHEVs will be used. And the company will conduct similar field tests in Torrance, the US, by using three EVs and three PHEVs.


It is also planning to conduct field tests in Stamford, the US, by using the “EV-neo” electric two-wheeled vehicle and the “Monpal ML200? electric cart in addition to EVs and PHEVs.


“Though we have not determined a specific period of time for the tests, it will be about two years,” the company said.


In Saitama Prefecture, the vehicles will be tested in various areas depending on their characteristics. For example, in Saitama City, Honda will examine how the EV and the electric two-wheeled vehicle can be selectively used in the areas around train stations.


In Kumagaya City, Honda will test the “Park & Ride” system, which combines EVs, PHEVs and trains in the area around the Kagohara Station. In Chichibu City, the company will establish a system by using the Monpal.


This time, Honda also disclosed a charging station equipped with photovoltaic batteries developed by Honda Soltec Co Ltd. The station has a rapid charger manufactured by Kyuki Corp, a subsidiary of Kyushu Electric Power Co Inc, and three normal chargers manufactured by Nihon Unisys Ltd.


“Supposing that an EV travels 40km per day, we would like to supply electricity to four EVs by using only solar batteries,” Ito said.


As for charging technologies, Honda developed a system to monitor the use of chargers, etc in real time by using car navigation systems and smartphones. The system utilizes the company’s “Internavi Premium Club” telematics service, which uses a dedicated communication device equipped in the Fit.


Moreover, Honda mounted another communication device on vehicles to collect data on the use of automotive batteries.


SOURCE: TechOn


View the original article here

Thursday, March 15, 2012

Nasal Spray Testing System

        Upon being granted a patent for the core elements of its hardware and software spray pattern and plume geometry measurement systems, ImageTherm has announced availability of SprayVIEW version 4.


SprayVIEW automates, accelerates and increases the accuracy of the testing of pharmaceutical spray drug products, including nasal spray pumps, metered dose inhalers, and oral spray pumps, in accordance with the U.S. Food and Drug Administration (FDA) testing recommendations announced April 2003. SprayVIEW's objective testing methodology enables innovator and generic pharmaceutical companies to more quickly and effectively evaluate drug formulations with a 98 percent accuracy and repeatability rate. It reduces overall lab testing time by 10x, as compared to earlier methods, helping to bring safe and effective pharmaceutical spray drug products to the consumer market faster.


"Since 1999, SprayVIEW has helped pharmaceutical companies, such as GlaxoSmithKline, AstraZeneca and 3M, become more agile and competitive by streamlining their testing and analysis processes," said Dino J. Farina, president of ImageTherm. "We have already seen proven results from 60 worldwide end-user customers throughout North America, Europe, Asia and the United Kingdom using SprayVIEW."


For decades, the pharmaceutical industry has endured the use of thin layer chromatography (TLC)-plate spray pattern, still image photographic testing and paper-based records as drug characterization and reporting techniques. Meanwhile, the FDA now recommends the electronic and automated documentation of spray characterization data for drug products. With existing archaic and time-consuming techniques being very qualitative and subjective, and with the industry's need to address current and future FDA guidelines, pharmaceutical companies require a methodology and associated technology to analyze spray characterization automatically, non-destructively and quantitatively. The unique, patented technology in SprayVIEW enables completely non-intrusive and objective measurements of spray pattern and plume geometry for pharmaceutical sprays.


Version 4 of SprayVIEW improves the acquisition, handling, analysis and reporting of spray test data and allows pharmaceutical companies to maintain compliance with the 21 CFR Part 11 regulation. It revolutionizes test data management and reporting by incorporating a secure Oracle client-server database architecture.


The system: Enables 21 CFR Part 11 Compliance - SprayVIEW 4 allows pharmaceutical companies to fully comply with 21 CFR Part 11 regulations for electronic records and electronic signatures. In SprayVIEW 4, test data and images are collected in a compliant manner and form the basis of the electronic records submitted to the FDA.Offers Improved Data Handling Capabilities - In SprayVIEW 4, all spray data are stored in a secure Oracle database, Version 10g, alleviating companies from the burden of storing large individual files. In addition, the software architecture allows for future inclusion of data from other actuation events (i.e. unit dose measurement, droplet size distribution and cascade impaction).Includes a Method Editor - SprayVIEW 4 decreases the amount of operator time and intervention required during measurement taking by introducing a method editor that automates data acquisitions tasks. The method editor helps the user define the test instructions and then automatically execute them. Automatic system checks and calibrations ensure data integrity.Incorporates Advanced Reporting and Analysis Tools - Advanced software functionality enables users to easily sort, compare and analyze spray data in a Windows-based graphical user interface.

ImageTherm was the first company to develop an integrated hardware and software system for pharmaceutical spray characterization and analysis. R&D directors, lab managers and production managers at innovator and generic pharmaceutical companies use this unique system to simplify the testing of spray pattern and plume geometry by using a laser light sheet to illuminate a non-intrusive plane of spray droplets or particles, enabling faster product time to market with significant improved quality control and regulatory compliance. To date, more than 30 pharmaceutical spray drugs, including Flonase, FluMist, Rhinocort Aqua and Proventil have been tested using ImageTherm's technology.


"With SprayVIEW 4, ImageTherm is setting a new standard for automating the collection and analysis of testing data for spray and aerosol drugs," said Rob Lewis, laboratory services manager at Fleming & Company Pharmaceuticals, makers of Ocean saline nasal spray. "SprayVIEW 4's advanced data handling capabilities, 21 CFR Part 11-compliant methodologies and integration of an Oracle database makes a very impressive package for companies seeking a more efficient, effective way to test and characterize nasal spray and pulmonary pharmaceuticals."


ImageTherm delivers innovative testing and development systems and services that are advancing the science of nasal and pulmonary spray delivery of pharmaceuticals.


View the original article here